Regulations are necessary to prevent unsafe products from killing people; regulations are killing
small life sciences companies and the patients they might have otherwise saved.
Not exact matches
In a year that saw a terrible Ebola pandemic in Africa and the resurgence of Legionnaire's disease in New York, it's
small wonder that
life sciences and health - care
companies are also leading the way for initial public offerings.
The 56
companies on our 2017 Change the World list, which includes six
smaller rising stars, are tackling problems obvious and not - so - obvious — from Accenture, which is using data to reduce E.R. visits, to DSM, a Dutch
life sciences company, that is fighting greenhouse gas emissions from a notorious source: cow flatulence.
For
life -
science companies, it also provides configurable laboratory space, hundreds of thousands of dollars of shared laboratory equipment, and a unique «Innovation Lab» that even provides access to
small equipment and reagents, helping early - stage
companies bridge that critical gap between late - stage academic research and early - stage product development.
This is one of many
small blind spots in the
life sciences, places where the lack of basic development, documentation, and tooling has led to
company after
company, research group after research group deciding to do something else with their limited funds rather than be forced into building every last part of the basic toolkit they'd need to even get started.
A
small sample of
companies Chris has represented in publicly filed matters includes: Wells Fargo, N.A., Future Income Payments, LLC, Meridian Senior
Living, Mecklenburg County, Caliber Home Loans, Inc., Grandfather Home for Children, Inc., Branch Bank and Trust Corp., AscendOne Corp., Mecklenburg County, UNC Health Systems, Consert, Inc., Snug Harbor on Nelson Bay, Inc., and Bayer Crop
Science.
Our clients range from medical device and pharmaceutical manufacturers to
companies focusing on diagnostic testing, biologics, biosimilars and
small molecules, among other areas of the
life sciences industry.
Although the Morristown, N.J. - based firm is significantly
smaller than the top 20 firms in the index, Porzio's diverse
life sciences practice demonstrates that sophisticated transactional, regulatory and compliance services throughout a
company life cycle are not exclusive to the legal industry's Goliaths.
For its public offering, Spotify has taken an unconventional and somewhat risky approach called direct listing, a route normally taken by
small - cap
companies, usually in biotech and
life sciences.
As
smaller companies,
life science startups often require their people to engage in contact across both the business and scientific communities.
We represent
companies that range in size from
small technology start - ups to Fortune 1000
companies across a wide spectrum of industries, including software,
life sciences, medical devices, professional services, financial services, construction, manufacturing, retail, non-profit and healthcare.